Objective: The staging of multiple pulmonary adenocarcinomas requires the distinction of intrapulmonary metastasis (IPM) from multiple primary lung cancers (MPLCs). This can be challenging in some patients, and the addition of data from oncogenic driver mutations in these tumors may be helpful in this determination.
Introduction
Synchronous (simultaneous) or metachronous (sequential) primary lung cancers represent a diagnostic and therapeutic dilemma in thoracic oncology. Differentiating synchronous primary lesions from intrapulmonary metastasis (IPM) or metachronous primaries from disease recurrence is challenging when tumor histologic features represent a common subtype. This distinction is of critical importance, as it directly affects TNM staging and therefore clinical management. Patients with multiple primary lung cancers (MPLCs) are generally treated with aggressive local therapy in pursuit of cure, whereas those with metastatic disease receive systemic therapy, often with palliative intent.
MPLCs cannot be reliably distinguished from intrapulmonary metastases on the basis of clinical or radiographic features alone. The original criteria for diagnosis of MPLCs were proposed by Martini and Melamed in 1975 . 1 These guidelines state that tumors with the same histologic features may be considered synchronous (or metachronous with a disease-free interval longer than 2 years) if they are found in a different segment, lobe, or lung with no carcinoma found in common lymphatics and no evidence for extrapulmonary metastasis at diagnosis. Although these criteria are relatively simple to apply and have been in mainstream use since the mid-1970s, they have proved insufficient for staging multifocal lesions. The distinction between MPLC and metastasis is currently made on the basis of clinical and pathologic assumptions that may vary between chest physicians. There is no standardized ancillary test that can be used to answer this question with a high degree of clinical accuracy.
The seventh edition of the American Joint Committee on Cancer (AJCC) TNM classification for lung cancer, which went into effect in January 2010, made important revisions for the staging of multiple tumor nodules on the basis of overall survival among pathologically staged cases. 2 These changes have helped refine the prognosis for patients with MPLC. Previous series have suggested that despite a presumption of metastasis, in what is an aggressive malignancy, many patients with nodenegative nonsolitary adenocarcinomas have the same excellent prognosis as those with solitary lesions, an observation that supports MPLC rather than true IPM. 3 The converse has also been observed; however, some patients with a clinical diagnosis of MPLC demonstrate extremely poor long-term survival, even when both nodules are independently classified as stage I, highlighting the limitations of the Martini and Melamed critiera. 4, 5 Several molecular methods have been explored as a means to refine multifocal lung cancer staging (see Discussion). Emerging data support the notion that molecular analysis of somatic changes within tumor DNA has the potential to improve diagnostic classification of MPLC, but these techniques have not yet found their way into mainstream clinical use. However, patients with lung cancer of the adenocarcinoma histologic subtype are now routinely tested for a panel of oncogenic driver mutations (in genes such as EGFR, KRAS, ALK receptor tyrosine kinase gene (ALK), and BRAF), which if present may serve as biomarkers for therapeutic response to targeted agents in the advanced setting. These mutations are of significant interest in the study of synchronous/ metachronous lung adenocarcinomas, as they are known to be early events in carcinogenesis (i.e., they are acquired before clonal expansion and should not differ between primary lesions and metastases). [6] [7] [8] In this study, we compared clinical, histologic, and molecular staging systems in a set of patients who presented with synchronous or metachronous pulmonary carcinoma, predominantly adenocarcinomas. For molecular staging, we analyzed driver oncogenic mutations in separate nodules and assessed concordance. We first performed the same analysis in an unrelated cohort of patients with adenocarcinoma with nodal or distant metastases, to establish proof of principle that these driver mutations are detectable and consistent across different samples of primary tumor and metastasis. With this baseline information, we then hypothesized that this approach could distinguish MPLC from IPM and recurrence from new primary carcinoma.
Materials and Methods

Patient Cohorts
Data from pathology reports and corresponding molecular reports were retrospectively obtained from lung cancer resections from 2005 to 2014 to build two patient cohorts. Most case samples were lung adenocarcinoma biopsy specimens or resections that were also referred for molecular testing from formalin-fixed paraffin-embedded tissue blocks or cell blocks from cytologic samples. Clinicopathologic data for all cases were obtained. Overall survival data were obtained as of March 2015 by using death registry and hospital visit data, after which all were de-identified.
The first cohort consisted of 45 patients with locally advanced or metastatic lung adenocarcinoma. In each case, tissue biopsy specimens from the primary lesion, nodal metastasis, or distant metastasis were analyzed. Represented metastatic sites included lymph node, pleura, effusion, adrenal, bone, liver, omentum, ascites, and brain. The second cohort consisted of 69 patients with 154 synchronous or metachronous lung adenocarcinomas (anywhere from two to four nodules per case; one nodule was squamous carcinoma). All nodules were sampled by either core biopsy or surgical resection, with most having surgical resection. All patients in cohort 2 had a standard preoperative work-up to determine regional and systemic disease along with nodal staging as part of the primary tumor resection.
Traditional Clinical Staging
Patients in cohort 1 were selected on the basis of review of clinical mutation testing having been performed on more than one tumor sampling. This included small-sample testing versus resection, as well as sampling of primary tumor, nodal, and/or distant metastasis. In this group, there was no expectation or history of MPLC either clinically or pathologically. Patients in cohort 2 were each assigned a highest potential clinical T or M category based on the anatomic location of their multifocal lesions, as per the AJCC seventh TNM classification for lung cancer; specifically, T3 if both or all nodules were found in the same lobe, T4 if nodules were found in a different lobe of the ipsilateral lung, or M1 if nodules were identified in both lungs. Metachronous cases were assigned recurrence as the highest potential clinical staging category.
Histologic Staging
Standard histologic review was performed on all tissue samples to ensure correct histologic classification, with immunohistochemistry (thyroid transcription factor 1 and p63/p40) and mucicarmine as needed. For cohort 1, most of the patients had at least one small sample, limiting the analysis to the category of adenocarcinoma without predominant pattern assessment. For cohort 2, the predominant histologic subtype in each nodule was identified. Represented patterns included acinar, solid, papillary, invasive mucinous, micropapillary, adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and nonmucinous lepidic. Each case in cohort 2 was then assigned a histologic T category. MPLC was histologically indicated by either of the following: (1) either of the paired nodules were AIS or MIA or (2) the predominant pattern was different between paired nodules.
Molecular Staging
All tissue samples in both cohorts had mutational analysis performed for EGFR (exons 18-21) by Sanger sequencing and KRAS (exons 2-3) by amplification refractory mutation system methodology or Sanger sequencing. Analysis for ALK by fluorescence in situ hybridization and BRAF (V600E) by amplification refractory mutation system methodology was performed. All cases were reviewed for adequate cellularity as part of the molecular laboratory workflow. Most cases were enriched for tumor by manual microdissection. In cohort 1, mutational concordance was assessed between tested samples. Each patient in cohort 2 was assigned a molecular stage. MPLC was chosen as the molecular classification if paired nodules harbored differing mutations, or if a mutation was present in one nodule and the other was wild type (WT). If both lesions were pan-WT, the molecular status was considered noninformative (NI).
The histologic and molecular schema used to differentiate MPLC from IPM (or disease recurrence) in cohort 2 is summarized in Figure 1 .
Results
Cohort 1
Patient characteristics for the first cohort (n ¼ 45) are summarized in Table 1 . All tissue samples demonstrated adenocarcinoma by histologic testing. On molecular assessment of primary lesions, 12 patients (26.7%) were found to have an EGFR mutation, 12 (26.7%) were found to have a KRAS mutation, and one (2.2%) had an ALK rearrangement. The remaining 20 patients were WT for all mutations tested (44.4%). Of the 25 patients with oncogenic driver mutations, analysis of the matched sample revealed an identical mutation in 24 of 25 cases; one core biopsy showed EGFR L858R mutation not found on resection specimen. This represents a concordance rate of 96% and supports the hypothesis that oncogenic driver mutations are detected in multiple samples from the same tumor, nodes, and metastasis. It also considers absence of mutation in both nodules as NI.
Cohort 2
The patients in cohort 2 (n ¼ 69) were divided into three subcohorts on the basis of their highest potential clinical stage: T3, T4/M1a, or recurrence. Staging data for each of these groups are summarized in Tables 2  through 4 . Table 2 lists 52 synchronous lung nodules in 25 patients in whom the highest potential T category was T3 (i.e., both or all nodules in the same lobe). Thirteen of 25 cases (52%) met histologic criteria for MPLC because of either differing predominant subtype between a nodule pair or presence of AIS or MIA. Discordant mutational analysis between nodule pairs was observed in nine of 25 cases (36%), suggesting MPLC by molecular staging. In six of 25 cases (24%), both nodules had pan-WT status, an NI molecular analysis result. In the remaining 10 cases (40%), identical driver mutations were identified in paired nodules, supporting a diagnosis of intralobar metastasis (true T3). Thus, for the subset of patients with presumed clinical T3 disease, the concordance rate between this T3 designation and molecular staging was 57.9% (11 of 19 cases with informative Table 3 lists 62 synchronous lung nodules in 27 patients with a highest potential clinical stage of T4 (different lobe in ipsilateral lung) or M1a (contralateral lung). In this subcohort, 18 of 27 cases (66.7%) were histologically determined to be MPLC, whereas 22 of 27 cases (81.5%) were molecularly identified as MPLC on the basis of discordant driver mutation status. Three cases (11.1%) had NI molecular staging. Only two patients in this subset were found to have T4 disease on the basis of a matching non-WT molecular profile between paired nodules; in one molecular T4 case with three nodules, two were the same and one was different. Thus, when NI cases were excluded, the concordance rate between potential T4/M1 status and molecular staging was only 8.4% (two of 24 cases). Histologic and molecular staging were concordant in 16 of 24 cases (66.6%). Table 4 lists 17 patients with 40 metachronous lung nodules, with the highest potential clinical stage being disease recurrence. Four of these patients (cases 9, 13, 23, and 41) initially presented with a pair of synchronous tumors, with a third nodule developing later in metachronous fashion. One patient (case 17) had a total of four nodules (two synchronous and two metachronous). In these instances, the highest potential clinical stage was T3 or T4 for the synchronous cancers and recurrence for the subsequent lesion(s). Ten of the 17 cases (58.8%) met histologic criteria for metachronous MPLC rather than true recurrence. Molecular analysis supported metachronous MPLC in nine cases (52.9%), and it was NI in two cases (11.7%). In case 9, molecular analysis was NI for the metachronous lesion (nodule 3) but identified MPLC for the initial synchronous tumor pair (nodules 1 and 2). Overall, the concordance rate between clinical and molecular staging (when informative) was 42.8% (six of 14 cases). Histologic and molecular staging were concordant in 10 cases (71.4%) . Table 5 summarizes the rate of concordance for different staging approaches in both cohorts.
The additional information of nodal status was not consistently helpful. Cases with node metastasis are highlighted in bold in Tables 2 to 4 . Among the potential T3 cases, lymph node involvement was seen in five cases, with histologic analysis predicting MPLC in two of five cases and molecular analysis predicting MPLC in one of four informative cases. Among the node-positive potential T4/M1 cases, histologic analysis predicted MPLC in two of four cases, and molecular analysis in four of four cases. For metachronous lesions in which the original tumor was node positive, both histologic and molecular analysis predicted MPLC in one of three cases.
Another observation among the set of molecularly distinct nodules in individual patients is the type of mutation seen in nodules from the same patient. When WT cases were excluded, 17 patients had different KRAS or different EGFR mutations whereas three patients had a KRAS and an EGFR mutation. Of the patients with multiple KRAS mutations, eight had pairs of transversion mutations, and three had two transversion mutations and one transition mutation. Only one patient had one transversion and one transition mutation. Of the three patients with both EGFR and KRAS mutations, two had transition-type KRAS mutations and one had a rare consecutive base mutation.
Examination of cases in which histologic and molecular findings were discordant revealed several categories. The first is that nonmucinous lepidic predominant adenocarcinomas were MPLC by molecular analysis, despite their histologic similarity. The other is the detection of a relatively common molecular alteration in both nodules, which may not be adequate evidence of a metastatic focus.
Examination of overall survival data was complex, and there were too few events to examine individual stage/recurrence categories. However, overall survival at 2 years was 100% among 52 patients, 95% at 3 years among 41 patients, and 80% at 4 years among 31 patients followed up for the respective durations after the initial operation.
Discussion
In 2010, the seventh TNM classification for lung cancer revised the staging of multiple tumor nodules with multiple same-lobe nodules categorized as T3 (previously T4) and the finding of additional nodules in other lobes of the ipsilateral lung designated as T4 (previously M1). These changes were made on the basis of overall survival data among pathologically staged cases, which demonstrated that patients determined to have T4 tumors because of additional same-lobe nodules had survival similar to that of patients with T3 tumors (p ¼ 0.2838) and markedly improved survival compared with that of patients staged T4 for other reasons (p ¼ 0.0029). Similarly, patients who were staged M1 because of ipsilateral different-lobe nodules had survival similar to that of the comparator T4 patients-both groups had 5-year survival rates of 22% (p ¼ 0.41). 2 These data supported the recharacterization to ultimately down-stage these scenarios.
Although MPLC has historically been considered a rare phenomenon, it has been reported with increasing frequency because of improved diagnostic and surveillance mechanisms. [9] [10] [11] As low-dose computed tomography gains mainstream acceptance as a screening modality, we anticipate that nodule discovery and MPLC 
a Case numbers in bold are lymph node-positive cases. adeno, adenocarcinoma; cyto, cytologic; D, discordant; C, concordant; NI, noninformative; WT, wild type; AIS, adenocarcinoma in situ.
incidence will continue to rise. 12, 13 Recent data suggest that as many as 20% of patients in the screening population will be found to have synchronous or metachronous tumors, 14, 15 although the International Association for the Study of Lung Cancer staging database reports this finding in 3.5% of patients, 16 highlighting the impact of multiple nodules in a screening population.
Misclassifying MPLCs as metastases (or vice versa) can lead to significant clinical consequences. Understaged disease may result in avoidable surgical morbidity whereas overstaging may result in missed opportunities for curative therapy. Traditional clinicopathologic criteria fall short when it comes to making the distinction with agreement level of clinical and pathologic staging of NSCLC as low as 35% to 55%. 17 In this study, we demonstrate a significant discrepancy between clinicopathologic and molecular staging in a series of 69 patients with 154 synchronous or metachronous lung adenocarcinomas. The mutations in EGFR, KRAS, ALK, and BRAF occur early in tumorigenesis (i.e., before clonal expansion), such that heterogeneous distribution of these derangements is uncommon. [18] [19] [20] Furthermore, these gene mutations generally occur in a mutually exclusive fashion. Genomic analysis of tumor pairs in cohort 1, consisting of samples from primary lesion as well as metastasis, functioned as our control set, in which 96% mutational concordance was demonstrated across 25 patients with driver mutations. This result is in distinction to that which was reported by Schmid et al., 21 with a relatively low concordance in EGFR and KRAS mutations between primary tumors and metastasis.
Of the samples from the 69 patients in cohort 2, 12 yielded NI molecular results. This occurred in instances in which both nodules were WT across all genes tested. This scenario does not facilitate distinction between MPLC and metastasis, as two pan-WT lesions could still be clonally distinct from one another. We found that the highest potential clinical stage and molecular stage were concordant in only 28.1% of the remaining 57 cases. Histologic staging (based on the predominant morphologic pattern observed in paired nodules) performed better but was far from perfect-overall concordance between histologic and molecular staging was 68.4%. This held true in each of the three subcohorts-histologic-molecular concordance was always higher than highest potential T or M category versus molecular: 73.7 versus 57.9%, 66.6% versus 8.4%, and 71.4 versus 42.8% for T3, T4/M1a, and recurrence, respectively. In a series of tumors published by Schneider et al. from the University of Pittsburgh, concordance of morphologic and molecular classification in adenocarcinoma was 89%, which is somewhat higher than in our series. 22 Also of interest was an inability to demonstrate survival impact on the basis of molecular restaging in the Pittsburgh cohort. In a series of 44 tumors in 18 patients, Walts et al. also showed that patients with multiple nodules had overall survival at 10 years similar to that of stage I controls and distinct from that of patients with stage II to IV disease. 23 Arai et al. 24 also noted that intrapulmonary same-lobe nodules as a T3 designation had better survival than other T3 disease. In our series, overall survival data did not have a number of events needed to assess survival impact on the basis of histologic or molecular restaging approach, but the overall survival of 100% at 2 years and 80% at 4 years is higher than expected for a cohort of T3 and T4 disease by multiple nodules. For example, Rami-Porta et al. demonstrated a 2-year survival of about 60% for same-lobe nodules and 40% for same-side nodules. 2 In the forthcoming eighth edition of TNM classification for lung cancer, there are no recommended changes for the classification of separate tumor nodules. 16 However, for multifocal ground glass/lepidic tumors, a T category determined by the highest T lesion with either the number of nodules or the letter m (denoting multifocal) in parentheses-T1a(3) or T1b(m)-has been proposed. 25 Our data indicating that predominant nonmucinous lepidic tumors were molecularly distinct in the informative cases support that approach to not upstage lepidic predominant tumors despite histologic similarity. Classification of the categories T AIS and T MIA as MPLC has been incorporated into our algorithm.
The additional information of positive nodal status did not uniformly predict molecular similarity among same-lobe and different-lobe nodules. However, involvement of a common nodal bed is considered evidence in favor of T4 or M1 disease, and a surprising number of the node positive cases had molecularly distinct pulmonary nodules. This calls into question the meaning of node-positive tumor in the analysis of MPLC versus pulmonary metastasis, which in the current AJCC staging supports pulmonary metastasis in multiple nodules in different lobes or lungs.
It is of considerable interest that the clinical/molecular concordance rate was dramatically lower among [26] [27] [28] This selection of patients can lead to undertreatment in a subset in which MPLC is not suspected.
With the advent of molecular pathology, we are now able to ask iterative questions regarding the fundamental molecular differences between synchronous/ metachronous MPLC and lung cancer metastases. [29] [30] [31] Girard et al. used array comparative genomic hybridization to determine whether synchronous/metachronous lung tumors represent independent primaries or metastasis; they found that genomic profiling contradicted the clinicopathologic diagnosis in 18% of cases, suggesting that array comparative genomic hybridization may yield a more accurate classification. 32 Comparative mutational profiling was also used to determine tumor lineage in 24 pathologically inconclusive cases presenting with either two lung lesions or a head and neck cancer and a lung lesion. DNA sequencing of specific oncogene point mutations and a panel of allelic imbalance markers revealed that 15 cases (63%) were mutationally discordant, representing independent primaries. 33 Vignot et al. compared genomic alterations in primary and matched metastatic tumor pairs from 15 patients with NSCLC. Using a targeted next-generation sequencing assay, they demonstrated a 94% concordance in recurrent somatic mutations between tumor pairs, further demonstrating that the genomic profile of a metastasis reflects that of the primary. 8 More recently, a diagnostic lineage test based on chromosomal rearrangements from mate-pair sequencing was developed to distinguish MPLC from metastasis. 34 A recent series described microRNA profiling as potentially useful. 35 A large next-generation sequencing approach on 15 independent primaries in six patients was recently undertaken, and the results were compared with those in The Tumor Genome Atlas lung adenocarcinoma series. The approach supported independent synchronous lung primaries, and in addition, it showed that independent tumors from the same patient were no more similar to each other than random patient tumors selected from The Tumor Genome Atlas series. 36 Although only six patients were involved, this is of interest in consideration of common carcinogenesis within one patient (such as cigarette smoking).
Most cases with mutation positivity in more than one nodule involved either KRAS or EGFR mutation. This may reflect the different underlying cause of these mutations-smoking in the case of KRAS mutation and unknown for EGFR mutation. It is of interest that two of the three cases with EGFR and KRAS mutations had transition-type KRAS mutation, which is not considered to be smoking associated. Furthermore, most of the cases with different KRAS mutation were of the smokingassociated transversion type, perhaps indicating a smoking-associated field effect. These were still informative, as they were different mutations, albeit with a common carcinogenic origin.
There are several limitations of this study that must be considered. Our sample size was relatively small, and the retrospective design may have resulted in selection bias. In addition, the retrospective nature limited annotation of cigarette smoking history. Because only four oncogenic driver genes were analyzed, a number of cases were NI in terms of molecular staging; use of a larger gene panel is a strong consideration. A larger cohort with longer follow-up is ultimately needed to validate our findings. Lastly, there is a probability of a tumor pair having a matching driver mutation by chance alone, on the basis of the observed frequency of a given alteration. For example, the KRAS G12D mutation is estimated to occur in 5.2% of lung adenocarcinomas. 37 If nodule 1 harbors this mutation, the probability that nodule 2 will independently (without being of the same lineage) carry the same derangement is 0.052. For more common alterations, such as KRAS G12C or EGFR L858R, molecular concordance could still represent MPLC. This limitation can be confounded by common pathogenesis, such as smoking-associated KRAS mutation.
As promising as such techniques may be, none has entered routine clinical practice. That being said, the data presented here and by others demonstrate that staging for a sizeable fraction of multifocal adenocarcinoma cases, including ones with discrepant histologic subtypes, can be resolved by mutational analysis of EGFR, KRAS, ALK, and BRAF alone. We advocate that this degree of molecular interrogation is worthwhile upfront for patients with synchronous or metachronous adenocarcinomas and should be performed reflexively (as has become standard in the metastatic setting). A multistep molecular algorithm in which only the cases that are not resolved by routine driver mutation testing proceed to a more granular molecular analysis for the final distinction could ultimately be envisioned.
In conclusion, our analysis highlights a clear unmet clinical need for patients who present with synchronous or metachronous malignant lung nodules. These patients are at significant risk for erroneous staging, which is an unacceptable mistake to make in the era of molecular oncology. Comprehensive molecular analysis of somatic changes within tumor DNA should allow for precise classification of second tumors as either metastases or independent primaries. The time has come for a refined and efficient molecular staging technique to be introduced into routine clinical practice.
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